Dengue virus premembrane protein (prM) (prM)

The Dengue virus premembrane (prM) protein is a critical structural glycoprotein found in all four serotypes of the Dengue virus (DENV-1 to DENV-4) (1.1.1, 1.3.5). It serves as a molecular chaperone for the envelope (E) protein, ensuring its proper folding and assembly into heterodimers within the endoplasmic reticulum (1.3.2, 1.3.4). A primary biological function of prM is to shield the fusion loop of the E protein, preventing premature, low-pH-triggered membrane fusion as the nascent virion traverses the acidic secretory pathway of the host cell (1.3.2, 1.3.5). During the maturation process in the trans-Golgi network, prM is cleaved by the host protease furin into the pr peptide and the mature M protein, a step essential for the virus to become fully infectious (1.3.5, 1.4.1). In the context of disease, prM is a major target of the human immune response; however, antibodies directed against prM are frequently cross-reactive across serotypes but possess poor neutralizing capacity (1.1.3, 1.4.1). This characteristic is a central driver of antibody-dependent enhancement (ADE), where sub-neutralizing antibodies facilitate viral entry into Fc-receptor-bearing immune cells, potentially leading to severe manifestations like Dengue Hemorrhagic Fever (1.1.3, 1.4.3). Consequently, prM is a focal point in vaccine design, such as in the tetravalent Dengvaxia vaccine, which incorporates prM and E sequences to elicit protective immunity (1.1.1, 1.3.4). While it is a target for therapeutic antibodies and experimental entry inhibitors, the risk of ADE remains a significant safety concern and a challenge for drug development (1.1.3, 1.4.2).

Other names

prM proteinPremembrane proteinDengue virus prMprM/M proteinPrecursor membrane protein

Vaccine antigen for inducing neutralizing antibodies and T-cell responses; target for experimental entry inhibitors and protein degraders.